AFCAPS/TexCAPSAir Force Coronary/Texas Atherosclerosis Prevention Study. A clinical trial used to assess primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels.
Conclusion Lovastatin reduces LDL-C by 25%, raises HDL-C by 6%, and decreases major acute coronary events, unstable angina, coronary revascularization, coronary events, and other vascular events.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.